Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Clin Cancer Res October 1 2015 21 (19) 4245-4245;

Editorial

  • Editorial | Free Article
    AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine
    Kenneth C. Anderson
    Clin Cancer Res October 1 2015 21 (19) 4247-4247; DOI:10.1158/1078-0432.CCR-15-1978

CCR 20th Anniversary Commentary

  • CCR 20th Anniversary Commentary | Free Article
    CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma—The Progress and the Limitations
    Nataliya Mar, Annick Desjardins and James J. Vredenburgh
    Clin Cancer Res October 1 2015 21 (19) 4248-4250; DOI:10.1158/1078-0432.CCR-15-1381

CCR Translations

  • CCR Translations
    Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
    Andrea van Elsas, Hans van Eenennaam and John B. Haanen
    Clin Cancer Res October 1 2015 21 (19) 4251-4253; DOI:10.1158/1078-0432.CCR-15-1126

  • CCR Translations
    Next Generation of Preclinical Liver Cancer Models
    Achim Weber, Tracy O'Connor and Mathias Heikenwalder
    Clin Cancer Res October 1 2015 21 (19) 4254-4256; DOI:10.1158/1078-0432.CCR-15-1152

CCR Perspectives in Drug Approval

  • CCR Perspectives in Drug Approval
    FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
    Geoffrey Kim, Gwynn Ison, Amy E. McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip, Haw-Jyh Chiu, Tiffany K. Ricks, Todd Palmby, Anne Marie Russell, Gaetan Ladouceur, Elimika Pfuma, Hongshan Li, Liang Zhao, Qi Liu, Rajesh Venugopal, Amna Ibrahim and Richard Pazdur
    Clin Cancer Res October 1 2015 21 (19) 4257-4261; DOI:10.1158/1078-0432.CCR-15-0887

CCR Drug Updates

  • CCR Drug Updates
    Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia
    Ofir Wolach and Richard M. Stone
    Clin Cancer Res October 1 2015 21 (19) 4262-4269; DOI:10.1158/1078-0432.CCR-15-0125

Molecular Pathways

  • Molecular Pathways
    Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade
    Wade T. Iams and Christine M. Lovly
    Clin Cancer Res October 1 2015 21 (19) 4270-4277; DOI:10.1158/1078-0432.CCR-14-2518

  • Molecular Pathways
    Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment
    Stefania Scala
    Clin Cancer Res October 1 2015 21 (19) 4278-4285; DOI:10.1158/1078-0432.CCR-14-0914

Cancer Therapy: Clinical

  • Cancer Therapy: Clinical | AuthorChoice
    Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone and Anthony W. Tolcher
    Clin Cancer Res October 1 2015 21 (19) 4286-4293; DOI:10.1158/1078-0432.CCR-14-2607

  • Cancer Therapy: Clinical | AuthorChoice
    Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
    Corey Casper, Shalini Chaturvedi, Nikhil Munshi, Raymond Wong, Ming Qi, Michael Schaffer, Rajesh Bandekar, Brett Hall, Helgi van de Velde, Jessica Vermeulen, Manjula Reddy and Frits van Rhee
    Clin Cancer Res October 1 2015 21 (19) 4294-4304; DOI:10.1158/1078-0432.CCR-15-0134

  • Cancer Therapy: Clinical
    Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
    Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen Jr, Lea Krekow, Frankie Ann Holmes, Svetislava Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum and Stephen Jones
    Clin Cancer Res October 1 2015 21 (19) 4305-4311; DOI:10.1158/1078-0432.CCR-15-0636

  • Cancer Therapy: Clinical
    High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses
    Miriam E. Mossoba, David C. Halverson, Roger Kurlander, Bazetta Blacklock Schuver, Ashley Carpenter, Brenna Hansen, Seth M. Steinberg, Syed Abbas Ali, Nishant Tageja, Frances T. Hakim, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Dennis D. Hickstein, Steven Z. Pavletic, Hanh Khuu, Marianna Sabatini, David Stroncek, Bruce L. Levine, Carl H. June, Jacopo Mariotti, Olivier Rixe, Antonio Tito Fojo, Michael R. Bishop, Ronald E. Gress and Daniel H. Fowler
    Clin Cancer Res October 1 2015 21 (19) 4312-4320; DOI:10.1158/1078-0432.CCR-15-0340

  • Cancer Therapy: Clinical
    Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
    Primo N. Lara Jr, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp and David R. Gandara
    Clin Cancer Res October 1 2015 21 (19) 4321-4326; DOI:10.1158/1078-0432.CCR-14-3281

  • Cancer Therapy: Clinical
    Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
    Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Shinsuke Iida, Takashi Ishida, Takashi Kojima, Toshihiko Doi, Susumu Suzuki, Midori Isobe, Takeru Funakoshi, Kazuhiro Kakimi, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Ryuzo Ueda and Eiichi Nakayama
    Clin Cancer Res October 1 2015 21 (19) 4327-4336; DOI:10.1158/1078-0432.CCR-15-0357

Personalized Medicine and Imaging

  • Personalized Medicine and Imaging
    Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
    Masaaki Komatsu, Heather E. Wheeler, Suyoun Chung, Siew-Kee Low, Claudia Wing, Shannon M. Delaney, Lidija K. Gorsic, Atsushi Takahashi, Michiaki Kubo, Deanna L. Kroetz, Wei Zhang, Yusuke Nakamura and M. Eileen Dolan
    Clin Cancer Res October 1 2015 21 (19) 4337-4346; DOI:10.1158/1078-0432.CCR-15-0133

  • Personalized Medicine and Imaging | AuthorChoice
    Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions
    Andrew J. Radosevich, Nikhil N. Mutyal, Adam Eshein, The-Quyen Nguyen, Bradley Gould, Jeremy D. Rogers, Michael J. Goldberg, Laura K. Bianchi, Eugene F. Yen, Vani Konda, Douglas K. Rex, Jacques Van Dam, Vadim Backman and Hemant K. Roy
    Clin Cancer Res October 1 2015 21 (19) 4347-4355; DOI:10.1158/1078-0432.CCR-15-0136

  • Personalized Medicine and Imaging
    FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
    Friederike Göke, Alina Franzen, Trista K. Hinz, Lindsay A. Marek, Petros Yoon, Rakesh Sharma, Maike Bode, Anne von Maessenhausen, Brigitte Lankat-Buttgereit, Antonia Göke, Carsten Golletz, Robert Kirsten, Diana Boehm, Wenzel Vogel, Emily K. Kleczko, Justin R. Eagles, Fred R. Hirsch, Tobias Van Bremen, Friedrich Bootz, Andreas Schroeck, Jihye Kim, Aik-Choon Tan, Antonio Jimeno, Lynn E. Heasley and Sven Perner
    Clin Cancer Res October 1 2015 21 (19) 4356-4364; DOI:10.1158/1078-0432.CCR-14-3357

  • Personalized Medicine and Imaging
    Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
    Hua Yuan, Jiuan Chen, Yiqiang Liu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin and Yuntao Xie
    Clin Cancer Res October 1 2015 21 (19) 4365-4372; DOI:10.1158/1078-0432.CCR-14-3354

  • Personalized Medicine and Imaging
    Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI
    Benjamin M. Ellingson, Albert Lai, Huytram N. Nguyen, Phioanh L. Nghiemphu, Whitney B. Pope and Timothy F. Cloughesy
    Clin Cancer Res October 1 2015 21 (19) 4373-4383; DOI:10.1158/1078-0432.CCR-14-2862

  • Personalized Medicine and Imaging
    PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
    Elena Zamagni, Cristina Nanni, Katia Mancuso, Paola Tacchetti, Annalisa Pezzi, Lucia Pantani, Beatrice Zannetti, Ilaria Rambaldi, Annamaria Brioli, Serena Rocchi, Carolina Terragna, Marina Martello, Giulia Marzocchi, Enrica Borsi, Ilaria Rizzello, Stefano Fanti and Michele Cavo
    Clin Cancer Res October 1 2015 21 (19) 4384-4390; DOI:10.1158/1078-0432.CCR-15-0396

Cancer Therapy: Preclinical

  • Cancer Therapy: Preclinical
    Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma
    Matthew J. Barth, Cory Mavis, Myron S. Czuczman and Francisco J. Hernandez-Ilizaliturri
    Clin Cancer Res October 1 2015 21 (19) 4391-4397; DOI:10.1158/1078-0432.CCR-15-0056

  • Cancer Therapy: Preclinical
    β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
    Coral San Millán, Beatriz Soldevilla, Paloma Martín, Beatriz Gil-Calderón, Marta Compte, Belén Pérez-Sacristán, Encarnación Donoso, Cristina Peña, Jesús Romero, Fernando Granado-Lorencio, Félix Bonilla and Gemma Domínguez
    Clin Cancer Res October 1 2015 21 (19) 4398-4409; DOI:10.1158/1078-0432.CCR-14-2027

  • Cancer Therapy: Preclinical
    Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
    Erik C. Dreaden, Yi Wen Kong, Stephen W. Morton, Santiago Correa, Ki Young Choi, Kevin E. Shopsowitz, Kasper Renggli, Ronny Drapkin, Michael B. Yaffe and Paula T. Hammond
    Clin Cancer Res October 1 2015 21 (19) 4410-4419; DOI:10.1158/1078-0432.CCR-15-0013

  • Cancer Therapy: Preclinical
    Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
    Pinbo Huang, Baoxiong Zhuang, Heyun Zhang, Haiyan Yan, Zhiyu Xiao, Wenbin Li, Jianlong Zhang, Qibin Tang, Kaishun Hu, H. Phillip Koeffler, Jie Wang and Dong Yin
    Clin Cancer Res October 1 2015 21 (19) 4420-4430; DOI:10.1158/1078-0432.CCR-14-2067

  • Cancer Therapy: Preclinical
    Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
    Lindsey M. Draper, Mei Li M. Kwong, Alena Gros, Sanja Stevanović, Eric Tran, Sid Kerkar, Mark Raffeld, Steven A. Rosenberg and Christian S. Hinrichs
    Clin Cancer Res October 1 2015 21 (19) 4431-4439; DOI:10.1158/1078-0432.CCR-14-3341

  • Cancer Therapy: Preclinical
    Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib
    Claudia Groß, Katja Steiger, Sufyan Sayyed, Irina Heid, Annette Feuchtinger, Axel Walch, Julia Heß, Kristian Unger, Horst Zitzelsberger, Marcus Settles, Anna Melissa Schlitter, Juliane Dworniczak, Jennifer Altomonte, Oliver Ebert, Markus Schwaiger, Ernst Rummeny, Andreas Steingötter, Irene Esposito and Rickmer Braren
    Clin Cancer Res October 1 2015 21 (19) 4440-4450; DOI:10.1158/1078-0432.CCR-14-2018

Biology of Human Tumors

  • Biology of Human Tumors
    Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis
    Joakim Crona, Samuel Backman, Rajani Maharjan, Markus Mayrhofer, Peter Stålberg, Anders Isaksson, Per Hellman and Peyman Björklund
    Clin Cancer Res October 1 2015 21 (19) 4451-4460; DOI:10.1158/1078-0432.CCR-14-2854

  • Biology of Human Tumors
    Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
    Tae-Min Kim, Seung-Hyun Jung, Chang Hyeok An, Sung Hak Lee, In-Pyo Baek, Min Sung Kim, Sung-Won Park, Je-Keun Rhee, Sug-Hyung Lee and Yeun-Jun Chung
    Clin Cancer Res October 1 2015 21 (19) 4461-4472; DOI:10.1158/1078-0432.CCR-14-2413

  • Biology of Human Tumors
    New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
    John B. Kisiel, Massimo Raimondo, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney, Zhifu Sun, Sumit Middha, Saurabh Baheti, Hongzhi Zou, Thomas C. Smyrk, Lisa A. Boardman, Gloria M. Petersen and David A. Ahlquist
    Clin Cancer Res October 1 2015 21 (19) 4473-4481; DOI:10.1158/1078-0432.CCR-14-2469

  • Biology of Human Tumors
    Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
    Jiyoon Lee, Salvatore Condello, Bakhtiyor Yakubov, Robert Emerson, Andrea Caperell-Grant, Kiyotaka Hitomi, Jingwu Xie and Daniela Matei
    Clin Cancer Res October 1 2015 21 (19) 4482-4493; DOI:10.1158/1078-0432.CCR-15-0226

Letter to the Editor

  • Letter to the Editor
    Ancient Retrovirus Targeted by Engineered T Cells in Melanoma—Letter
    John M. Grange and Bernd Krone
    Clin Cancer Res October 1 2015 21 (19) 4494-4494; DOI:10.1158/1078-0432.CCR-15-1548

Corrections

  • Corrections
    Correction: Pancreatic Cancer-Derived Exosomes Causes Paraneoplastic β-cell Dysfunction
    Clin Cancer Res October 1 2015 21 (19) 4495-4495; DOI:10.1158/1078-0432.CCR-15-1524

  • Corrections
    Correction: The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients
    Clin Cancer Res October 1 2015 21 (19) 4496-4496; DOI:10.1158/1078-0432.CCR-15-1935

Back to top
PreviousNext
Clinical Cancer Research: 21 (19)
October 2015
Volume 21, Issue 19
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
  • Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
  • Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
  • Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis

Jump to

  • Highlights
  • Editorial
  • CCR 20th Anniversary Commentary
  • CCR Translations
  • CCR Perspectives in Drug Approval
  • CCR Drug Updates
  • Molecular Pathways
  • Cancer Therapy: Clinical
  • Personalized Medicine and Imaging
  • Cancer Therapy: Preclinical
  • Biology of Human Tumors
  • Letter to the Editor
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • Characterization of Glioblastoma Patient-Derived Xenografts
  • FLASH-RT Spares Lung Progenitor Cells
  • AR Gene Rearrangements in Prostate Cancer
  • PDAC and GATA6 Expression
  • Guadecitabine and Carboplatin in Ovarian Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement